Abstract: DNA sequences that increase peptide chain expression when operably linked to a gene encoding the peptide chain and methods of generating a peptide chain expression host cell using the foregoing are disclosed. Peptide chain expression host cells are also disclosed.
Type:
Grant
Filed:
August 11, 2006
Date of Patent:
March 3, 2009
Assignee:
Centocor, Inc.
Inventors:
Pamela H. Nelson, Gordon Moore, Barry A. Morse, Haimanti Dorai, Bernard Scallon, Linda Hendricks
Abstract: An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
Type:
Grant
Filed:
June 30, 2006
Date of Patent:
February 17, 2009
Assignee:
Centocor, Inc.
Inventors:
Jacqueline Benson, Mark Cunningham, Cynthia Duchala, Jill M. Giles-Komar, Jinquan Luo, Michael A. Rycyzyn, Sweet Raymond
Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Type:
Application
Filed:
December 7, 2007
Publication date:
January 22, 2009
Applicants:
Centocor, Inc., New York University
Inventors:
Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
Abstract: Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids encoding such CNGH0010 polypeptides and antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, are useful for therapeutic and diagnostic formulations, administration and devices. The aforesaid polypeptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-CNGH0010 antibodies. The CNGH0010 polypeptides and antibodies are used in modulating or treating at least one CNGH0010-related disease in a cell, tissue, organ, animal, or patient.
Type:
Grant
Filed:
February 28, 2007
Date of Patent:
January 20, 2009
Assignee:
Centocor, Inc.
Inventors:
Xiao-yu R. Song, Chong Huang, Keying Ma, Bailin Liang, Michael Naso
Abstract: Methods for altering the cellular secretion rate of a protein, such as an antibody and the altered cells produced by the method are disclosed. The methods and altered cells are useful for producing high levels of proteins for therapeutic, diagnostic or research purposes.
Type:
Grant
Filed:
March 31, 2005
Date of Patent:
January 20, 2009
Assignee:
Centocor, Inc.
Inventors:
Michael Rycyzyn, Gregory Bannish, Jill Giles-Komar
Abstract: The invention relates to the field of antibodies, and particularly to modified antibodies, methods of preparing modified antibodies and uses thereof. More particularly, the invention relates to the preparation of more active IgG antibodies by the addition of an extra immunoglobulin domain to the constant region.
Type:
Grant
Filed:
June 5, 2003
Date of Patent:
September 23, 2008
Assignee:
Centocor, Inc.
Inventors:
Bernard J. Scallon, Ann Cai, Michael Naso
Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Type:
Grant
Filed:
October 16, 2006
Date of Patent:
September 16, 2008
Assignees:
Centocor, Inc., New York University
Inventors:
Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Type:
Grant
Filed:
June 18, 2007
Date of Patent:
August 26, 2008
Assignees:
Centocor, Inc., New York University
Inventors:
Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Type:
Grant
Filed:
August 2, 2005
Date of Patent:
July 29, 2008
Assignees:
Centocor, Inc., New York University
Inventors:
Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
Abstract: The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Type:
Grant
Filed:
September 3, 2004
Date of Patent:
July 1, 2008
Assignee:
Centocor, Inc.
Inventors:
George A. Heavner, David M. Knight, John Ghrayeb, Bernard J. Scallon, Thomas C. Nesspor, Chichi Huang
Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Type:
Grant
Filed:
August 8, 2007
Date of Patent:
May 20, 2008
Assignees:
Centocor, Inc., New York University
Inventors:
Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
Abstract: The present invention relates to at least one novel anti-MCP-1 antibodies, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Abstract: The present invention relates to at least one novel RSV proteins, antibodies, including isolated nucleic acids that encode at least one RSV protein or antibody, RSV vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Abstract: The invention concerns antagonists of alphav-containing integrins which have therapeutic activity in oncology applications and methods for selecting such antagonists using a peptide which competes for alphaV-integrin binding with a known monoclonal antibody having demonstrated anti-tumor activity. The claimed peptide represents a conformational epitope or mimotope present on the ligand to which the therapeutic antibodies selectively bind.
Type:
Grant
Filed:
June 22, 2004
Date of Patent:
April 29, 2008
Assignee:
Centocor, Inc.
Inventors:
David Shealy, Sam Wu, Yan Chen, Audrey Baker
Abstract: Isolated polynucleotides encoding Cynomolgus monkey prostate specific antigen and polypeptides obtainable from the polynucleotides and uses are disclosed.
Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Type:
Grant
Filed:
December 4, 2006
Date of Patent:
February 26, 2008
Assignees:
Centocor, Inc., New York University
Inventors:
Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
Abstract: Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids encoding such CNGH0010 polypeptides and antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, are useful for therapeutic and diagnostic formulations, administration and devices. The aforesaid polypeptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-CNGH0010 antibodies. The CNGH0010 polypeptides and antibodies are used in modulating or treating at least one CNGH0010-related disease in a cell, tissue, organ, animal, or patient.
Type:
Grant
Filed:
April 30, 2004
Date of Patent:
February 5, 2008
Assignee:
Centocor, Inc.
Inventors:
Xiao-Yu Song, Chris Huang, Keying Ma, Bailin Liang, Michael Naso
Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?x-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Type:
Application
Filed:
April 10, 2006
Publication date:
December 27, 2007
Applicants:
Centocor, Inc., New York University
Inventors:
Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Type:
Grant
Filed:
October 26, 2002
Date of Patent:
November 6, 2007
Assignee:
Centocor, Inc.
Inventors:
Jill Giles-Komar, David Knight, David Peritt, Mohit Trikha
Abstract: The present invention relates to at least one novel anti-dual integrin antibodies, including isolated nucleic acids that encode at least one anti-dual integrin antibody, dual integrin, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Type:
Grant
Filed:
August 1, 2001
Date of Patent:
October 30, 2007
Assignee:
Centocor, Inc.
Inventors:
George Heavner, Jill Giles-Komar, Linda Snyder, Mohit Trikha